Paper41368010
Drug-resistant gram-negative bacterial infections in children in the Oceania region: review of the epidemiology, antimicrobial availability, treatment, clinical trial and pharmacokinetic data, and key evidence gaps.
Yeoh DK and 17 others. Lancet Reg Health West Pac, 2025. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Drug-resistant gram-negative bacterial infections in children in the Oceania region: review of the epidemiology, antimicrobial availability, treatment, clinical trial and pharmacokinetic data, and key evidence gaps. Papers, record 41368010. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41368010
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Drug-resistant gram-negative bacterial infections in children in the Oceania region: review of the epidemiology, antimicrobial availability, treatment, clinical trial and pharmacokinetic data, and key evidence gaps.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References91
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31122767 | Hard to study, hard to treat: putting children at the centre of antibiotic research and development. | Lancet Infect Dis | 2019 | https://conductscience.org/library/papers/31122767 | PubMed |
| 2 | 33603583 | Extended Infusion of Beta-Lactams Is Associated With Improved Outcomes in Pediatric Patients. | J Pediatr Pharmacol Ther | 2021 | https://conductscience.org/library/papers/33603583 | PubMed |
| 3 | 22249106 | Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. | Clin Ther | 2012 | https://conductscience.org/library/papers/22249106 | PubMed |
| 4 | 37190910 | A multicentre, retrospective audit of fosfomycin use for urinary tract infections in Australian children and adolescents. | J Antimicrob Chemother | 2023 | https://conductscience.org/library/papers/37190910 | PubMed |
| 5 | 39165021 | Australian Group on Antimicrobial Resistance surveillance outcome programs - bloodstream infections and antimicrobial resistance patterns from patients less than 18 years of age, January 2020 - December 2021. | Commun Dis Intell (2018) | 2024 | https://conductscience.org/library/papers/39165021 | PubMed |
| 6 | 27503642 | Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients. | Antimicrob Agents Chemother | 2016 | https://conductscience.org/library/papers/27503642 | PubMed |
| 7 | 32349993 | Antimicrobial resistance in the Pacific Island countries and territories. | BMJ Glob Health | 2020 | https://conductscience.org/library/papers/32349993 | PubMed |
| 8 | 28011614 | Dosing guidance for intravenous colistin in critically-ill patients. | Clin Infect Dis | 2017 | https://conductscience.org/library/papers/28011614 | PubMed |
| 9 | 20585118 | Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. | Antimicrob Agents Chemother | 2010 | https://conductscience.org/library/papers/20585118 | PubMed |
| 10 | 34051403 | Compassionate use of cefiderocol for VIM metallo-β-lactamase-producing Pseudomonas aeruginosa infection in a toddler with Burkitt lymphoma. | J Glob Antimicrob Resist | 2021 | https://conductscience.org/library/papers/34051403 | PubMed |
| 11 | 33313656 | Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections. | Clin Infect Dis | 2021 | https://conductscience.org/library/papers/33313656 | PubMed |
| 12 | 38516290 | The changing epidemiology of antimicrobial resistance in Fiji: a descriptive analysis of antimicrobial susceptibility and trends of endemic and emerging pathogens, 2019-2022. | Lancet Reg Health West Pac | 2024 | https://conductscience.org/library/papers/38516290 | PubMed |
| 13 | 31192975 | Safety and Efficacy of Tigecycline to Treat Multidrug-resistant Infections in Pediatrics: An Evidence Synthesis. | Pediatr Infect Dis J | 2019 | https://conductscience.org/library/papers/31192975 | PubMed |
| 14 | 34687548 | Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older. | Clin Pharmacol Ther | 2022 | https://conductscience.org/library/papers/34687548 | PubMed |
| 15 | 22354300 | In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. | Antimicrob Agents Chemother | 2012 | https://conductscience.org/library/papers/22354300 | PubMed |
| 16 | 35349496 | Infections Due to Antibiotic-resistant Gram-negative Bacteria in Pediatrics: Possible Management Strategies. | Pediatr Infect Dis J | 2022 | https://conductscience.org/library/papers/35349496 | PubMed |
| 17 | 35078765 | Randomised controlled trial of fosfomycin in neonatal sepsis: pharmacokinetics and safety in relation to sodium overload. | Arch Dis Child | 2022 | https://conductscience.org/library/papers/35078765 | PubMed |
| 18 | 38648808 | Tackling the threat of antimicrobial resistance in neonates and children: outcomes from the first WHO-convened Paediatric Drug Optimisation exercise for antibiotics. | Lancet Child Adolesc Health | 2024 | https://conductscience.org/library/papers/38648808 | PubMed |
| 19 | 35065702 | Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. | Lancet | 2022 | https://conductscience.org/library/papers/35065702 | PubMed |
| 20 | 38917034 | Characterization of Gram-negative Bloodstream Infections in Hospitalized Australian Children and Their Clinical Outcomes. | Clin Infect Dis | 2024 | https://conductscience.org/library/papers/38917034 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42538347 | Influence of probiotics on faecal antibiotic resistome in neonates: a systematic review. | Pediatr Res | 2026 | https://conductscience.org/library/papers/42538347 | PubMed |
| 42529261 | Comparative analysis of virulence and resistance gene profiles between carbapenem-resistant and ESBL-producing Escherichia coli. | Front Microbiol | 2026 | https://conductscience.org/library/papers/42529261 | PubMed |
| 41933301 | Risk factors for carbapenem-resistant Acinetobacter baumannii infection in children and A. baumannii-related mortality in the PICU: a retrospective study in Guangxi, China. | BMC Infect Dis | 2026 | https://conductscience.org/library/papers/41933301 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41368010
GET https://conductscience.org/api/papers/v1/41368010/references?page=2